ONEIL JAMES DENNEN,SHARMA SHALINI,ARUDCHANDRAN RAMACHANDRAN
申请号：
IN7373/DELNP/2010
公开号：
IN278529B
申请日:
2010.10.19
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
Uric acid in mammalian subjects is reduced and excretion-or uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is O, 1, 2 or 3 and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hydroxy, alkoxy having 1 or 2 carbon atoms, fluoro. chloro, bromo, and amino. A is phenyl unsubstituted or substituted by one, two or three groups selected from the group consisting of halo, alkyl having 1 or 2 carbon atoms. perfluoromethyL alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy or cycloalkyl having from 3 to 6 ring atoms wherein the cycloalky! is unsubstituted or one one two ring carbons are independently mono-substituted by methyl or ethyl or a 5 or 6 membered heleraromatic ring having 1 or 2 ring heteroatoms selected from N. S and O and the heteroaromatic ring is covalently bound to the remainder of the compound by a ring carbon.
